In fact a computer can generate you results too in this day and age of in-silico biology. ❋ Candid Engineer (2008)
Predicting these mutations in-silico purely from the genomic sequence is difficult due to an incomplete understanding of the multiple factors that may be responsible. ❋ Adam Woolfe (2010)
In our in-silico analysis we could not find PPARγ response elements (PPRE) in the 2.3 Kb upstream or even up to ~8. 8 kb upstream region of hres gene [22]. ❋ Anil K. Singh Et Al. (2010)
The company's unique integrated bio-process engineering platform allows "in-silico" ❋ Unknown (2010)
Enabling technologies include a series of technologies based on virtualisation, including in-silico testing and modelling and paperless office technologies. ❋ Unknown (2010)
Yang then performed laborious biological assays to see if the compounds lived up to their in-silico billing. ❋ Unknown (2010)
She/he is expected to have a strong background in biostatistics, in-silico ecology and/or population genetics, and molecular evolution. ❋ Unknown (2010)
B. subtilis molecular biology and experience of in-silico approaches to genetic system design, characterization and verification. ❋ Unknown (2010)
We, therefore, investigated the actual interaction, if any between resistin gene promoter and Sp1 factor, more so given the presence of Sp1 binding site predicted in-silico. ❋ Anil K. Singh Et Al. (2010)
Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the successful completion of the InnoMed PredTox Non-Clinical Safety Project organized around a series of animal studies using compounds terminated in drug development due to nephro - and hepatotoxicity. ❋ Unknown (2009)
These statements relate to, among other things, our expectations regarding our drug discovery efforts, the future development of our in-silico methodologies and the benefits of our collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. ❋ Unknown (2009)
Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Screener® 7.0, the latest version of its open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS) analysis. ❋ Unknown (2009)
Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the release of High Content Analyzer, the latest addition to the Genedata Screener® enterprise solution for high content screening (HCS) data analysis. ❋ Unknown (2009)
Leading provider of in-silico solutions releases high content screening module ❋ Unknown (2009)
Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in-silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. ❋ Unknown (2009)
Leading provider of in-silico solutions reaffirms ongoing support for non-clinical toxicology after promising collaboration results ❋ Unknown (2009)
